2月28日，药明生物(02269)盘中下跌5.07%，截至11:20，报22.45元/股，成交6.66亿元。
药明生物技术有限公司是全球领先的生物制剂服务供应商，提供全面、综合及高度定制的服务，包括从发现、开发到生产生物制剂的全过程。公司在2016年在中国生物制剂研发市场占有48%的市场份额，已与全球20大制药公司中的12家建立合作关系。
截至2024年中报，药明生物营业总收入85.74亿元、净利润14.99亿元。
3月25日，药明生物将披露2024财年年报。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.